TNFSF11 and breast cancer: Bone metastases, in patients with advanced breast cancer, are often treated with denosumab (trade name: Prolia® and Xgeva®), which is a human monoclonal antibody against receptor activator of nuclear factor-kappa B ligand (RANK-L) [274].